Folgen
David van de Vijver
David van de Vijver
Associate professor, Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, The
Bestätigte E-Mail-Adresse bei erasmusmc.nl - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
10472009
Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets
VJ Munster, E de Wit, JMA van den Brand, S Herfst, EJA Schrauwen, ...
Science 325 (5939), 481-483, 2009
7482009
An automated genotyping system for analysis of HIV-1 and other microbial sequences
T De Oliveira, K Deforche, S Cassol, M Salminen, D Paraskevis, ...
Bioinformatics 21 (19), 3797-3800, 2005
5562005
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ...
The Journal of infectious diseases 192 (6), 958-966, 2005
5532005
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ...
Nature communications 12 (1), 1-6, 2021
5042021
Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures
MK Hayden, MJM Bonten, DW Blom, EA Lyle, DAMC van de Vijver, ...
Clinical Infectious Diseases 42 (11), 1552-1560, 2006
5042006
Transmission of drug-resistant HIV-1 is stabilizing in Europe
J Vercauteren, AMJ Wensing, DAMC van de Vijver, J Albert, C Balotta, ...
The Journal of infectious diseases 200 (10), 1503-1508, 2009
3012009
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis
SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ...
PLoS medicine 12 (4), e1001810, 2015
2602015
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ...
The Lancet gastroenterology and hepatology, 2017
2592017
Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ...
MedRxiv, 2020
2392020
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical …
JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ...
The Lancet Global Health 2 (1), e23-e34, 2014
2222014
Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world
D Frentz, CA Boucher, DA Van De Vijver
AIDs Rev 14 (1), 17-27, 2012
1972012
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ...
Clinical infectious diseases 62 (5), 655-663, 2016
1712016
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
AB Abecasis, AMJ Wensing, D Paraskevis, J Vercauteren, K Theys, ...
Retrovirology 10 (1), 1-13, 2013
1682013
Sustainable HIV treatment in Africa through viral-load-informed differentiated care
A Phillips, A Shroufi, L Vojnov, J Cohn, T Roberts, T Ellman, K Bonner, ...
Nature 528 (7580), S68-S76, 2015
1572015
Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy
A Boerekamps, GE van den Berk, FN Lauw, EM Leyten, ME van Kasteren, ...
Clinical Infectious Diseases 66 (9), 1360-1365, 2018
150*2018
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
D Paraskevis, O Pybus, G Magiorkinis, A Hatzakis, AMJ Wensing, ...
Retrovirology 6 (1), 1-11, 2009
1452009
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
DA van de Vijver, AMJ Wensing, G Angarano, B Åsjö, C Balotta, E Boeri, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (3), 352-360, 2006
1382006
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
BE Nichols, CAB Boucher, M van der Valk, BJA Rijnders, ...
The Lancet Infectious Diseases 16 (12), 1423-1429, 2016
1092016
Stochastic simulation of HIV population dynamics through complex network modelling
PMA Sloot, SV Ivanov, AV Boukhanovsky, DAMC van de Vijver, ...
International Journal of Computer Mathematics 85 (8), 1175-1187, 2008
1052008
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20